Ensysce Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENSC Nasdaq 2836 www.ensysce.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ensysce Biosciences, Inc.

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study - Apr 16th, 2026 6:00 am
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs - Apr 7th, 2026 6:00 am
ENSC Making Great Strides Toward Commercialization - Mar 31st, 2026 5:08 am
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Mar 30th, 2026 2:50 pm
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans - Mar 4th, 2026 6:45 am
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology - Mar 3rd, 2026 6:00 am
Update: Wall Street Set to Open Lower Friday as Investors Analyze Higher Than Expected Producer Prices; Oil Prices Surge - Feb 27th, 2026 8:41 am
BC-Most Active Stocks - Feb 27th, 2026 8:30 am
Wall Street Set to Open Lower Friday as Investors Analyze Higher Than Expected Producer Prices; Oil Prices Surge - Feb 27th, 2026 7:28 am
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Feb 25th, 2026 6:00 am
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Feb 23rd, 2026 6:00 am
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Jan 28th, 2026 6:00 am
Ensysce Biosciences Expands Global Opioid Patent Portfolio - Jan 21st, 2026 6:00 am
ENSC Expands its Global Patent Portfolio - Jan 21st, 2026 4:47 am
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection - Jan 8th, 2026 6:00 am
Ensysce Biosciences Issues Annual Shareholder Letter - Jan 5th, 2026 6:00 am
Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC) - Dec 12th, 2025 6:00 am
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Dec 9th, 2025 6:00 am
ENSC Enrolls First Patient in Critical Phase 3 Trial - Dec 9th, 2025 4:24 am
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology - Dec 2nd, 2025 6:00 am